Key Clinical Summary: The Evidence Pulse - Translating Obesity Science

This is a micro-learning module summary of a presentation by Dr Fatima Cody Stanford which you can find here. Before participating, please read our CME and disclosure information which can be found here.

This activity is supported by an independent medical educational grant from Lilly. This online education program has been designed for healthcare professionals globally (except the UK).

Clinical Trial Insights and Treat-to-Target Strategies

REDEFINE 1 Trial (CagriSema): This 68-week study evaluated CagriSema (a fixed-dose combination of 2.4 mg cagrilintide and 2.4 mg semaglutide) against its individual monotherapies and a placebo in adults with a BMI ≥ 30 kg/m² (or ≥ 27 kg/m² with an obesity-related complication). CagriSema demonstrated superior clinical efficacy, enabling 41.4% of participants to achieve a BMI < 27 kg/m² and 29.4% to reach a strict, combined target of a BMI < 27 kg/m² alongside a waist-to-height ratio (WHtR) < 0.53. Achieving these dual anthropometric targets was strongly associated with near-normalization of cardiometabolic risk factors, including normoglycemia (achieved by 96.3% of target responders) and controlled triglycerides (97.7%).
OASIS 4 Trial (Oral Semaglutide): This 64-week trial assessed oral semaglutide 25 mg daily versus placebo in adults with overweight or obesity without type 2 diabetes. A notable 20.7% of participants treated with oral semaglutide achieved the combined target of a BMI < 27 kg/m² and a WHtR < 0.53. Among patients who successfully met these anthropometric goals, a significantly higher proportion achieved low-risk outcomes across critical cardiometabolic markers, including glycemia, blood pressure, and lipid profiles.
ATTAIN-1 Trial (Orforglipron and Quality of Life): This 72-week study evaluated the effects of orforglipron (an oral, small-molecule, non-peptide GLP-1 receptor agonist) compared to placebo on health-related quality of life (HRQoL). Pooled orforglipron doses demonstrated profound enhancements in patient-reported physical and psychosocial functioning. Significant score improvements were observed in key domains, including physical functioning, general health, vitality, and reduced bodily pain.

Key considerations:

Treating to specific anthropometric targets rather than focusing solely on overall weight loss, the clinical data from REDEFINE 1 and OASIS 4 confirm that a BMI < 27 kg/m² and a WHtR < 0.53 are achievable clinical endpoints that directly trigger broad metabolic normalization.
- These individualized anthropometric goals serve as reliable targets to guide treatment optimization decisions in general practice.
High-dose oral options like oral semaglutide 25 mg effectively expand the primary care toolkit, offering robust, non-injectable treatment paths that can significantly lower clinical barriers to initiating and maintaining long-term weight management.
Utilizing unique combination mechanisms, such as CagriSema, supports a chronic disease-oriented approach to obesity care by simultaneously driving improvements across body mass, fat distribution, and metabolic markers.
Validated quality-of-life and functional data from trials like ATTAIN-1 should be leveraged to discuss clear, function-based goals and to celebrate "non-scale-based victories" alongside standard metabolic metrics during shared decision-making.

Proactive Management and Dose Intensification

The STEP UP Trial (Semaglutide 7.2 mg): This trial examined the efficacy of an escalated once-weekly subcutaneous semaglutide dose of 7.2 mg compared to the standard 2.4 mg dose and placebo over 72 weeks in adults with obesity and a history of unsuccessful dietary weight-loss efforts. Semaglutide 7.2 mg delivered a superior mean body weight reduction of 20.7% from baseline, compared with 17.5% with the 2.4 mg dose. The study explored specialized questionnaires and found that the escalated 7.2 mg dose yielded the most significant long-term improvements in craving control, emotional eating, and uncontrolled eating patterns.

Key considerations:

Manage obesity with a proactive, chronic disease mindset rather than waiting to treat secondary complications reactively.
Closely evaluate a patient's treatment trajectory and actively consider dose escalation (e.g., transitioning to higher-dose semaglutide) when an obesity management medication (OMM) response plateaus.
Perceived control of eating, food noise, and specific cravings must be integrated directly into primary care treatment plans. Clinicians can use data demonstrating that higher incretin doses significantly reduce emotional and uncontrolled eating to help frame broader treatment benefits beyond the bathroom scale.

Efficacy of Maintenance and Relapse Prevention

SURMOUNT-MAINTAIN Trial (Tirzepatide Maintenance): This 112-week study featured a 60-week open-label tirzepatide induction phase, followed by a 52-week double-blind period where patients who achieved a weight plateau were randomized to continue their maximum tolerated dose (MTD of 10 mg or 15 mg), step down to a 5 mg dose, or switch to a placebo. Continuous treatment at the MTD sustained an impressive 22.4% total mean weight loss through week 112 and preserved comprehensive improvements in blood pressure, waist circumference, and lipid markers. Stepping down the dosage to 5 mg was an effective alternative, maintaining approximately 70.5% of the initial weight reduction and providing meaningful anthropometric benefits. Conversely, complete treatment discontinuation (the placebo group) led to substantial, rapid weight regain and a swift reversal of cardiometabolic benefits.
ATTAIN-MAINTAIN Trial (Injectable-to-Oral Transition): This phase 3b trial explored a maintenance strategy of switching patients who successfully achieved a ≥ 5% weight loss on injectable tirzepatide or semaglutide over to a daily oral non-peptide GLP-1 receptor agonist, orforglipron. Patients transitioned to oral orforglipron successfully maintained 78% of their prior tirzepatide-induced weight loss and 82% of their semaglutide-induced weight loss at 52 weeks. The oral transition also sustained long-term reductions in waist circumference, blood pressure, and lipid profiles.
BELIEVE Study Extension (Body Composition Quality): This trial evaluated body composition changes via dual-energy X-ray absorptiometry (DXA) during a 72-week treatment period and a subsequent 6-month treatment withdrawal phase. It compared semaglutide, bimagrumab (an investigational monoclonal antibody that blocks activin type 2 receptors to promote skeletal muscle hypertrophy), and their combination. Bimagrumab monotherapy and combination therapy led to significant additive total fat mass loss, alongside preservation and gain of lean skeletal muscle mass. Upon complete treatment withdrawal, partial weight regain occurred; however, the fat-to-lean mass ratio of the regained weight matched the loss phase, indicating that stopping appetite-regulating therapies does not lead to preferential fat regain.

Key considerations:

Obesity must be continuously framed to patients as a chronic, biology-driven medical condition that necessitates long-term, uninterrupted therapy. Stopping therapy abruptly leads to an immediate and substantial weight recurrence risk, which must be clearly discussed during shared decision-making.
Continuous full-dose therapy preserves the greatest metabolic and physical benefits. However, if full-dose continuation is completely unfeasible due to cost, coverage, or patient preference, PCPs should offer a structured dose reduction (such as tirzepatide 5 mg) as a viable, patient-centered step-down path rather than total discontinuation.
Transitioning from injectable therapies to advanced daily oral agents (such as orforglipron) represents a highly effective clinical option to sustain weight-loss gains and metabolic improvements, significantly boosting long-term treatment adherence.
PCPs should closely monitor emerging medical evidence on combination approaches that specifically optimize body composition (fat loss paired with skeletal muscle preservation) rather than relying on weight loss alone on a standard scale.

Optimizing Persistence, Adherence, and Tolerability

Roczen NHS Digital Service Study: This real-world, retrospective analysis evaluated state-funded patients using incretin therapies within a high-engagement digital specialist obesity service. The service integrated a tightly coordinated multidisciplinary team (MDT) featuring general practitioners, bariatric specialists, dietitians, and psychologists to deliver proactive medication and lifestyle support. This highly engaged care model achieved an outstanding 96.1% treatment adherence rate over 24 weeks. Crucially, statistical analysis confirmed that the frequency or severity of reported adverse events had no negative impact on patient retention or overall weight-loss outcomes.
Large DWLP Retrospective Analysis: A real-world UK study of 110,141 adults who initiated tirzepatide within a digital weight-loss program (DWLP) examined how patient-set goals and active digital engagement drive long-term compliance. Patients who established larger initial total body weight-loss targets (20% to 40%) before starting therapy demonstrated a significantly lower risk of treatment discontinuation. Furthermore, meaningful digital engagement (coaching attendance, app logins, and regular weight logging) was associated with a 49% reduced hazard of discontinuing medication. It extended a patient's time on therapy by an average of 3 months across all goal groups.
The EASO/EFAD/ECPO Consensus Framework: This major joint consensus statement establishes a practical, 3-component care framework designed to be integrated alongside obesity management pharmacotherapy from day one:
- Nutritional Component: Proactively manage transient gastrointestinal side effects by employing flexible, gradual dose-escalation schedules and counseling patients to eat smaller, nutrient-dense meals 3 to 6 times per day. Clinical focus must be on maintaining high dietary quality, ensuring adequate fluid and fiber intake, and prescribing a daily complete multivitamin to safeguard against micronutrient deficiencies actively.
- Functional Component: Implement a dual prescription to directly counter lean tissue mass loss, sarcopenia, and declines in physical strength. This comprises a daily protein prescription of 1.0 to 1.5 g/kg of adjusted body weight (with an absolute minimum floor of 60 g/day distributed across meals) combined with an exercise prescription consisting of resistance training 2 to 3 times per week and 150 to 300 minutes of weekly aerobic activity. Clinicians should monitor physical strength via simple, repeatable functional tests (such as grip strength and the 5x sit-to-stand test) and target a 3:1 fat-to-fat-free mass loss ratio.
- Psychological Component: Because modern incretin-based therapies act directly on central nervous system pathways to suppress "food noise," routine psychological screening is essential. PCPs must conduct baseline and ongoing screening at clinical milestones to evaluate patient coping mechanisms, shifting body images, disordered eating patterns, depression, anxiety, and potential substance abuse to triage vulnerable patients to professional psychological support properly.

Key considerations:

Structured multidisciplinary clinical support, active dose titration, and proactive symptom management matter more to patient compliance than simply avoiding side effects entirely. PCPs can achieve better real-world adherence rates by offering supportive care pathways that empower patients to manage expected gastrointestinal symptoms.
Detailed goal-setting discussions must be structured at the time of treatment initiation. Helping patients articulate clear weight-loss expectations and coupling therapy with digital touchpoints are independent, real-world predictors of a longer duration of therapy.

Delivering Patient-Centered, Bias-Aware Care

Healthcare Provider Weight Stigma: Comprehensive clinical presentations emphasize that weight bias remains common among healthcare professionals, severely undermining the quality of clinical care and driving poor patient outcomes. Patients with higher body weight frequently experience judgment, oversimplification, and blame within primary care encounters.
Stigma Reduction Interventions: Data from targeted medical interventions (such as studies from the Mayo Clinic) prove that provider bias can be significantly mitigated through structured behavioral techniques. Implementing specific strategies—including explicit perspective-taking, fostering a common in-group identity, practicing clinical emotion regulation, questioning default assumptions regarding willpower, and directly addressing stigmatizing clinic design elements—substantially improves a clinician’s preparedness, confidence, and objective capacity to deliver supportive, non-stigmatizing care.

Key considerations:

Deep, conscious self-awareness of implicit weight bias is an absolute prerequisite for delivering safe and effective obesity management. PCPs must recognize that implicit or explicit bias directly fractures the patient-provider relationship, leading to reduced clinical trust, poor communication, lowered patient engagement, and a high rate of follow-up attrition.
PCPs should adopt evidence-based clinical techniques, such as imagining themselves in the patient's shoes (perspective-taking), practicing proactive emotional regulation before entering an encounter, and actively questioning default clinical assumptions regarding a patient's personal willpower or lifestyle choices.
The physical clinic environment itself is a central component of the therapeutic relationship. Practices must proactively signal respect and build systemic trust by sourcing properly sized clinical equipment (such as appropriate seating and gowns), ensuring the absolute use of objective, non-judgmental language, and directly validating a patient's past negative experiences with healthcare stigma.

Content is accurate as of the date of publication.